PPARgamma was originally identified to stimulate the renin production during screening of the effect of free fatty acids on renin in an attempt to identify mechanisms responsible for the development of arterial hypertension during obesity [18]. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.